Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03435250
Title Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Agios Pharmaceuticals, Inc.
Indications

pancreatic ductal adenocarcinoma

Advanced Solid Tumor

lymphoma

lung non-small cell carcinoma

Therapies

AG-270 + Docetaxel

AG-270 + Gemcitabine + Nab-paclitaxel

AG-270

Age Groups: senior | adult
Covered Countries USA | FRA | ESP

Facility Status City State Zip Country Details
Yale University New Haven Connecticut 06519 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Beth Israel Boston Massachusetts 02215 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Memorial Sloan Kettering Cance Center New York New York 10065 United States Details
Sarah Cannon Cancer Center Nashville Tennessee 37203 United States Details
Institut Gustave Roussy Villejuif Cedex 94805 France Details
Hospital Universitario Vall d'Hebron Barcelona 08035 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field